USFDA completes inspection of Jubilant Pharmova's API manufacturing facility

  • India Infoline News Service |
  • 15 Dec, 2022 |
  • 9:16 AM
Jubilant Pharmova Limited announced that inspection of the Active Pharmaceutical Ingredients (API) manufacturing facility at Nanjangud on December 13, 2022 by the United States Food and Drug Administration (USFDA) has concluded.

Accordingly, the USFDA has issued eight observations pursuant to the completion of the inspection. The company will submit an action plan on the observations and will engage with USFDA for next steps.

At around 9:16 AM, Jubilant Pharmova was trading at Rs410 per share higher by 1.30% on the BSE.

For feedback and suggestions, write to us at

Invest wise with Expert advice

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
ad IconAd Image

Most Read News

Article Image
  • 14 March, 2022 |
  • 7:03 AM

The US Federal committee's meeting will conclude on March 16, 2022.

Most Shared News

No Record Found